Trial · NCT00042224
Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
NCT00042224, Phase 1, Phase 2, Completed, Northwell Health; results first posted 2015-10-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Electroconvulsive Therapy in Clozapine Refractory Schizophrenia. Trials, record NCT00042224. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00042224
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
- NCT number
- NCT00042224
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 39 participants, actual
- Lead sponsor
- Northwell Health
- Conditions
- Schizophrenia
- Interventions
- Electroconvulsive Therapy (ECT), Clozapine
- First posted
- 2002-07-26
- Last updated
- 2017-05-15
- Results first posted
- 2015-10-15
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. | 8 Weeks | Response is defined as 40% reduction of symptoms in the psychotic symptom sub-scale (hallucinatory behavior, suspiciousness, conceptual disorganization, and unusual thought of content) of the Brief Psychiatric Rating Scale (BPRS) at the end of the 8-week study. BPRS assesses psychotic symptoms on a 18-item scale. The severity of each item is rated on a continuous scale from 1-7, with 1 being the least severe and 7 being most severe. Participants included in the study, at baseline had at least a moderate score of 4 on one of the four psychotic symptom sub-scale or a score of 12 on all four of these items combined (ranges 4 -28, with higher scores indicative of greater severity). A reduction of symptoms would be a sub-scale score which is 40% less than participants baseline score. If a participant enters the study with a sub-scale score of 15, to be considered a responder (at least a 40% reduction in symptoms score) his/her score must decrease by at least 6 points and be 9 or less. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. | 8 Weeks | inpatient units of the Zucker Hillside Hospital at Glen Oaks, N.Y., and the Pilgrim State Psychiatric Center in Long Island, N.Y. | Percentage of responders | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. | Electroconvulsive Therapy With Medication | 50 | Percentage of responders | ||
| Response Rates in the ECT Plus Clozapine Group vs the Pharmacotherapy Group. | Medication Monotherapy | 0 | Percentage of responders |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 1 Electroconvulsive Therapy With Medication | 20 | |
| Overall Study | STARTED | 2 Medication Monotherapy | 19 | |
| Overall Study | COMPLETED | 1 Electroconvulsive Therapy With Medication | 17 | |
| Overall Study | COMPLETED | 2 Medication Monotherapy | 16 | |
| Overall Study | NOT COMPLETED | 1 Electroconvulsive Therapy With Medication | 3 | |
| Overall Study | NOT COMPLETED | 2 Medication Monotherapy | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Electroconvulsive Therapy With Medication | ||
| Total, all-cause mortality | Medication Monotherapy | ||
| Total, other adverse events | Electroconvulsive Therapy With Medication | 0 | 20 |
| Total, other adverse events | Medication Monotherapy | 0 | 19 |
| Total, serious adverse events | Electroconvulsive Therapy With Medication | 0 | 20 |
| Total, serious adverse events | Medication Monotherapy | 0 | 19 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH060390 | ECT IN CLOZAPINE REFRACTORY SCHIZOPHRENIA | PETRIDES, GEORGIOS | LONG ISLAND JEWISH MEDICAL CENTER | NATIONAL INSTITUTE OF MENTAL HEALTH | 2001 to 2003 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Electroconvulsive Therapy With Medication vs Medication Monotherapy: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00042224
GET https://conductscience.org/api/trials/v1/NCT00042224/registered